Due to the lack of an appropriate dosage strength, Velphoro is not approved in pediatric patients 6 years to less than 9 years of age. The Food and Drug Administration (FDA) has expanded the approval ...
ST. GALLEN, Switzerland--(BUSINESS WIRE)--Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that the U.S. District Court for the District of Delaware issued a judgment in VFMCRP’s ...
ST. GALLEN, Switzerland--(BUSINESS WIRE)--Regulatory News: Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced positive results from a phase-III study in China (PA-CL-CHINA-01), ...
Please provide your email address to receive an email when new articles are posted on . WASHINGTON — Use of the sucroferric oxyhydroxide binder by Fresenius Medical Care Renal Therapies Group, ...
Please provide your email address to receive an email when new articles are posted on . Vifor Pharma's Phase III study on its hyperphosphatemia treatment in chronic kidney disease patients has been ...
WALTHAM, Mass., March 31, 2020 /PRNewswire/ -- A new retrospective data analysis published in Kidney Medicine shows that a higher percentage of hemodialysis patients prescribed Velphoro ® (sucroferric ...
SHENZHEN, CHINA, Feb. 03, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 2 February 2024, the Group through its wholly-owned ...
The US Food and Drug Administration (FDA) has approved sucroferric oxyhydroxide (Velphoro, Vifor Fresenius Medical Care Renal Pharma) for treatment of hyperphosphatemia in patients with chronic kidney ...
Call it a bad day for Teva and a good one for CSL Vifor. A Delaware district court ruled that a proposed Teva generic of CSL Vifor’s chronic kidney (CKD) drug Velphoro infringes an existing patent.
Regulators in Europe have given the green light to Vifor Fresenius Medical Care Renal Pharma's hyperphosphatemia drug Velphoro. Regulators in Europe have given the green light to Vifor Fresenius ...
St. Gallen, Switzerland, 30 April 2021 –Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced positive results from a phase-III study in China (PA-CL-CHINA-01), evaluating the efficacy of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results